Last data update: Nov 11, 2024. (Total: 48109 publications since 2009)
Records 1-13 (of 13 Records) |
Query Trace: Slifka KJ[original query] |
---|
Optimizing the implementation of Enhanced Barrier Precautions in community-based nursing homes
Mayoryk S , O'Hara LM , Robinson GL , Lydecker AD , Slifka KJ , Jones H , Roghmann MC . Am J Infect Control 2024 BACKGROUND: Enhanced Barrier Precautions (EBP) recommends using gowns and gloves for certain nursing home residents during specific high-contact care activities associated with multidrug-resistant organism (MDRO) transmission. Though EBP is included in CDC guidance as an MDRO control strategy, optimal implementation approaches remain unclear. METHODS: We implemented a quality improvement initiative using the 4E process model (Engagement, Education, Execution, and Evaluation) to optimize EBP implementation in four Maryland nursing homes. Semi-structured interviews with healthcare personnel (HCP) occurred to understand EBP acceptability. RESULTS: Glove use during high-contact care increased from 85% in the baseline to 97% during the intervention (p<0.01). Gown use increased from 27% to 78% (p<0.01). Accuracy of identifying residents eligible for EBP improved from 63% to 99% (p<0.01). Of 780 residents observed, one-third met EBP indications - MDRO colonization (21%), indwelling medical device (14%), and/or chronic wound (10%). The most noted facilitator to EBP implementation included HCP perception that EBP reduces MDRO transmission to other residents and staff. The most noted barrier was uncomfortable gowns. CONCLUSIONS: Implementation was complex and required comprehensive assessments of barriers and facilitators within each facility. HCP interviews identified common barriers and facilitators of EBP that can inform future EBP implementation projects. |
Measuring the direct medical costs of hospital-onset infections using an analogy costing framework
Scott RD 2nd , Culler SD , Baggs J , Reddy SC , Slifka KJ , Magill SS , Kazakova SV , Jernigan JA , Nelson RE , Rosenman RE , Wandschneider PR . Pharmacoeconomics 2024 BACKGROUND: The majority of recent estimates on the direct medical cost attributable to hospital-onset infections (HOIs) has focused on device- or procedure-associated HOIs. The attributable costs of HOIs that are not associated with device use or procedures have not been extensively studied. OBJECTIVE: We developed simulation models of attributable cost for 16 HOIs and estimated the total direct medical cost, including nondevice-related HOIs in the USA for 2011 and 2015. DATA AND METHODS: We used total discharge costs associated with HOI-related hospitalization from the National Inpatient Sample and applied an analogy costing methodology to develop simulation models of the costs attributable to HOIs. The mean attributable cost estimate from the simulation analysis was then multiplied by previously published estimates of the number of HOIs for 2011 and 2015 to generate national estimates of direct medical costs. RESULTS: After adjusting all estimates to 2017 US dollars, attributable cost estimates for select nondevice-related infections attributable cost estimates ranged from $7661 for ear, eye, nose, throat, and mouth (EENTM) infections to $27,709 for cardiovascular system infections in 2011; and from $8394 for EENTM to $26,445 for central nervous system infections in 2016 (based on 2015 incidence data). The national direct medical costs for all HOIs were $14.6 billion in 2011 and $12.1 billion in 2016. Nondevice- and nonprocedure-associated HOIs comprise approximately 26-28% of total HOI costs. CONCLUSION: Results suggest that nondevice- and nonprocedure-related HOIs result in considerable costs to the healthcare system. |
COVID-19 vaccination coverage, and rates of SARS-CoV-2 infection and COVID-19-associated hospitalization among residents in nursing homes - National Healthcare Safety Network, United States, October 2023-February 2024
Franklin D , Barbre K , Rowe TA , Reses HE , Massey J , Meng L , Dollard P , Dubendris H , Stillions M , Robinson L , Clerville JW , Slifka KJ , Benin A , Bell JM . MMWR Morb Mortal Wkly Rep 2024 73 (15) 339-344 Nursing home residents are at increased risk for developing severe COVID-19. Nursing homes report weekly facility-level data on SARS-CoV-2 infections, COVID-19-associated hospitalizations, and COVID-19 vaccination coverage among residents to CDC's National Healthcare Safety Network. This analysis describes rates of incident SARS-CoV-2 infection, rates of incident COVID-19-associated hospitalization, and COVID-19 vaccination coverage during October 16, 2023-February 11, 2024. Weekly rates of SARS-CoV-2 infection ranged from 61.4 to 133.8 per 10,000 nursing home residents. The weekly percentage of facilities reporting one or more incident SARS-CoV-2 infections ranged from 14.9% to 26.1%. Weekly rates of COVID-19-associated hospitalization ranged from 3.8 to 7.1 per 10,000 residents, and the weekly percentage of facilities reporting one or more COVID-19-associated hospitalizations ranged from 2.6% to 4.7%. By February 11, 2024, 40.5% of nursing home residents had received a dose of the updated 2023-2024 COVID-19 vaccine that was first recommended in September 2023. Although the peak rate of SARS-CoV-2 infection among nursing home residents was lower during the 2023-24 respiratory virus season than during the three previous respiratory virus seasons, nursing home residents continued to be disproportionately affected by SARS-CoV-2 infection and related severe outcomes. Vaccination coverage remains suboptimal in this population. Ongoing surveillance for SARS-CoV-2 infections and COVID-19-associated hospitalizations in this population is necessary to develop and evaluate evidence-based interventions for protecting nursing home residents. |
Modeling the impact of vaccination strategies for nursing homes in the context of increased SARS-CoV-2 community transmission and variants (preprint)
Holmdahl I , Kahn R , Slifka KJ , Dooling K , Slayton RB . medRxiv 2021 Nursing homes (NH) were among the first settings to receive COVID-19 vaccines in the United States, but staff vaccination coverage remains low at an average of 64%. Using an agent-based model, we examined the impact of community prevalence, the Delta variant, staff vaccination coverage, and boosters for residents on outbreak dynamics in nursing homes. We found that increased staff primary series coverage and high booster vaccine effectiveness (VE) in residents leads to fewer infections and that the cumulative incidence is highly dependent on community transmission. Despite high VE, high community transmission resulted in continued symptomatic infections in NHs. |
Effectiveness of COVID-19 mRNA vaccines against infection during an outbreak of SARS-CoV-2 Beta (B.1.351) variant in a skilled nursing facility - Virginia, March-April 2021.
Moline HL , Keaton A , Rice W , Varghese J , Deng L , Waters A , Barringer A , Winston D , Fields V , Slifka KJ , Verani JR , Schrag SJ , Jernigan J , Tate JE , Fleming-Dutra KE . Clin Infect Dis 2022 75 S155-S158 In April 2021, we assessed mRNA vaccine effectiveness (VE) in the context of a COVID-19 outbreak in a skilled nursing facility. Among 28 cases, genomic sequencing was performed on four specimens on four different patients, and all were classified by sequence analysis as the Beta (B.1.351) variant. Adjusted VE among residents was 65% (95% Confidence Interval: 25-84%). These findings underscore the importance of vaccination for prevention of COVID-19 in skilled nursing facilities. |
Remote Infection Control Assessments of US Nursing Homes During the COVID-19 Pandemic, April to June 2020.
Walters MS , Prestel C , Fike L , Shrivastwa N , Glowicz J , Benowitz I , Bulens S , Curren E , Dupont H , Marcenac P , Mahon G , Moorman A , Ogundimu A , Weil LM , Kuhar D , Cochran R , Schaefer M , Slifka KJ , Kallen A , Perz JF . J Am Med Dir Assoc 2022 23 (6) 909-916 e2 BACKGROUND: Nursing homes (NHs) provide care in a congregate setting for residents at high risk of severe outcomes from SARS-CoV-2 infection. In spring 2020, NHs were implementing new guidance to minimize SARS-CoV-2 spread among residents and staff. OBJECTIVE: To assess whether telephone and video-based infection control assessment and response (TeleICAR) strategies could efficiently assess NH preparedness and help resolve gaps. DESIGN: We incorporated Centers for Disease Control and Prevention COVID-19 guidance for NH into an assessment tool covering 6 domains: visitor restrictions; health care personnel COVID-19 training; resident education, monitoring, screening, and cohorting; personal protective equipment supply; core infection prevention and control (IPC); and communication to public health. We performed TeleICAR consultations on behalf of health departments. Adherence to each element was documented and recommendations provided to the facility. SETTING AND PARTICIPANTS: Health department-referred NHs that agreed to TeleICAR consultation. METHODS: We assessed overall numbers and proportions of NH that had not implemented each infection control element (gap) and proportion of NH that reported making ≥1 change in practice following the assessment. RESULTS: During April 13 to June 12, 2020, we completed TeleICAR consultations in 629 NHs across 19 states. Overall, 524 (83%) had ≥1 implementation gaps identified; the median number of gaps was 2 (interquartile range: 1-4). The domains with the greatest number of facilities with gaps were core IPC practices (428/625; 68%) and COVID-19 education, monitoring, screening, and cohorting of residents (291/620; 47%). CONCLUSIONS AND IMPLICATIONS: TeleICAR was an alternative to onsite infection control assessments that enabled public health to efficiently reach NHs across the United States early in the COVID-19 pandemic. Assessments identified widespread gaps in core IPC practices that put residents and staff at risk of infection. TeleICAR is an important strategy that leverages infection control expertise and can be useful in future efforts to improve NH IPC. |
Clinical outcomes of monoclonal antibody therapy during a COVID-19 outbreak in a skilled nursing facility-Arizona, 2021.
Dale AP , Hudson MJ , Armenta D , Friebus H , Ellingson KD , Davis K , Cullen T , Brady S , Komatsu KK , Stone ND , Uyeki TM , Slifka KJ , Perez-Velez CM , Keaton AA . J Am Geriatr Soc 2022 70 (4) 960-967 BACKGROUND: Adult residents of skilled nursing facilities (SNF) have experienced high morbidity and mortality from SARS-CoV-2 infection and are at increased risk for severe COVID-19 disease. Use of monoclonal antibody (mAb) treatment improves clinical outcomes among high-risk outpatients with mild-to-moderate COVID-19, but information on mAb effectiveness in SNF residents with COVID-19 is limited. We assessed outcomes in SNF residents with mild-to-moderate COVID-19 associated with an outbreak in Arizona during January-February 2021 that did and did not receive a mAb. METHODS: Medical records were reviewed to describe the effect of bamlanivimab therapy on COVID-19 mortality. Secondary outcomes included referral to an acute care setting and escalation of medical therapies at the SNF (e.g., new oxygen requirements). Residents treated with bamlanivimab were compared to residents who were eligible for treatment under the FDA's Emergency Use Authorization (EUA) but were not treated. Multivariable logistic regression was used to determine association between outcomes and treatment status. RESULTS: Seventy-five residents identified with COVID-19 during this outbreak met eligibility for mAb treatment, of whom 56 received bamlanivimab. Treated and untreated groups were similar in age and comorbidities associated with increased risk of severe COVID-19 disease. Treatment with bamlanivimab was associated with reduced 21-day mortality (adjusted OR=0.06; 95% CI: 0.01, 0.39) and lower odds of initiating oxygen therapy (adjusted OR=0.07; 95% CI: 0.02, 0.34). Referrals to acute care were not significantly different between treated and untreated residents. CONCLUSIONS: mAb therapy was successfully administered to SNF residents with COVID-19 in a large outbreak setting. Treatment with bamlanivimab reduced 21-day mortality and reduced initiation of oxygen therapy. As the COVID-19 pandemic evolves and newer immunotherapies gain FDA authorization, more studies of the effectiveness of mAb therapies for treating emerging SARS-CoV-2 variants of concern in high-risk congregate settings are needed. This article is protected by copyright. All rights reserved. |
Modeling the impact of vaccination strategies for nursing homes in the context of increased SARS-CoV-2 community transmission and variants.
Holmdahl I , Kahn R , Slifka KJ , Dooling K , Slayton RB . Clin Infect Dis 2022 75 (1) e880-e883 Using an agent-based model, we examined the impact of community prevalence, the Delta variant, staff vaccination coverage, and boosters for residents on outbreak dynamics in nursing homes. Increased staff coverage and high booster vaccine effectiveness leads to fewer infections, but cumulative incidence is highly dependent on community transmission. |
Administration of Bamlanivimab to Skilled Nursing Facility Residents During a COVID-19 Outbreak, January-February 2021, Arizona.
Dale AP , Hudson M , Cullen T , Ellingson K , Davis K , Armenta D , Friebus H , Currie C , Bhattarai R , Brady S , Komatsu K , Stone N , Uyeki T , Slifka KJ , Perez-Velez C , Keaton A . J Am Med Dir Assoc 2021 22 (7) 1357-1358 In November 2020, the Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for bamlanivimab, a monoclonal antibody (mAb), for treatment of mild to moderate COVID-19 in nonhospitalized individuals at high risk for severe disease.1 Since that time, several other mAb therapies, either alone or in combination, have also been issued EUA for use in the treatment of mild-to-moderate COVID-19.2 Although COVID-19 poses a high morbidity and mortality risk among older adult residents of long-term care facilities, reports on mAb use in the management of COVID-19 in skilled nursing facilities (SNFs) are limited, and perceived logistical barriers to on-site infusion of the mAb therapy may reduce their use in these settings.3 , 4 This letter describes the use of bamlanivimab during a large SARS-CoV-2 outbreak at a 270-bed SNF (Facility A). |
Investigation of a Suspect SARS-CoV-2 and Influenza A Mixed Outbreak: Lessons Learned for Long-Term Care Facilities Nationwide.
Schrodt CA , Malenfant JH , Hunter JC , Slifka KJ , Campbell A , Stone N , Whitehouse ER , Wittry B , Christensen B , Barnes JR , Brammer L , Hemarajata P , Green NM , Civen R , Gounder PP , Rao AK . Clin Infect Dis 2021 73 S77-S80 A suspected outbreak of influenza A and SARS-CoV-2 at a long-term care facility in Los Angeles County was months later, determined to not involve influenza. To prevent inadvertent transmission of infections, facilities should use highly specific influenza diagnostics and follow CDC guidelines that specifically address infection control challenges. |
Characterization of COVID-19 in Assisted Living Facilities - 39 States, October 2020.
Yi SH , See I , Kent AG , Vlachos N , Whitworth JC , Xu K , Gouin KA , Zhang S , Slifka KJ , Sauer AG , Kutty PK , Perz JF , Stone ND , Stuckey MJ . MMWR Morb Mortal Wkly Rep 2020 69 (46) 1730-1735 The coronavirus disease 2019 (COVID-19) pandemic has highlighted the vulnerability of residents and staff members in long-term care facilities (LTCFs) (1). Although skilled nursing facilities (SNFs) certified by the Centers for Medicare & Medicaid Services (CMS) have federal COVID-19 reporting requirements, national surveillance data are less readily available for other types of LTCFs, such as assisted living facilities (ALFs) and those providing similar residential care. However, many state and territorial health departments publicly report COVID-19 surveillance data across various types of LTCFs. These data were systematically retrieved from health department websites to characterize COVID-19 cases and deaths in ALF residents and staff members. Limited ALF COVID-19 data were available for 39 states, although reporting varied. By October 15, 2020, among 28,623 ALFs, 6,440 (22%) had at least one COVID-19 case among residents or staff members. Among the states with available data, the proportion of COVID-19 cases that were fatal was 21.2% for ALF residents, 0.3% for ALF staff members, and 2.5% overall for the general population of these states. To prevent the introduction and spread of SARS-CoV-2, the virus that causes COVID-19, in their facilities, ALFs should 1) identify a point of contact at the local health department; 2) educate residents, families, and staff members about COVID-19; 3) have a plan for visitor and staff member restrictions; 4) encourage social (physical) distancing and the use of masks, as appropriate; 5) implement recommended infection prevention and control practices and provide access to supplies; 6) rapidly identify and properly respond to suspected or confirmed COVID-19 cases in residents and staff members; and 7) conduct surveillance of COVID-19 cases and deaths, facility staffing, and supply information (2). |
Factors associated with Candida auris colonization and transmission in skilled nursing facilities with ventilator units, New York, 2016-2018
Rossow J , Ostrowsky B , Adams E , Greenko J , McDonald R , Vallabhaneni S , Forsberg K , Perez S , Lucas T , Alroy K , Slifka KJ , Walters M , Jackson BR , Quinn M , Chaturvedi S , Blog D . Clin Infect Dis 2020 72 (11) e753-e760 BACKGROUND: Candida auris is an emerging, multidrug-resistant yeast that spreads in healthcare settings. People colonized with C. auris can transmit this pathogen and are at risk for invasive infections. New York State (NYS) has the largest U.S. burden (>500 colonized and infected people); many colonized individuals are mechanically ventilated or have tracheostomy and are residents of ventilator-capable skilled nursing facilities (vSNF). We evaluated factors associated with C. auris colonization among vSNF residents to inform prevention interventions. METHODS: During 2016-2018, the NYS Department of Health conducted point prevalence surveys (PPS) to detect C. auris colonization among residents of vSNFs. In a case-control investigation, we defined a case as C. auris colonization in a resident and identified up to four residents with negative swabs during the same PPS as controls. We abstracted data from medical records on facility transfers, antimicrobials, and medical history. RESULTS: We included 60 cases and 218 controls identified from 6 vSNFs. After controlling for potential confounders, the following characteristics were associated with C. auris colonization: being on a ventilator (aOR: 5.9; CI: 2.3-15.4), receiving carbapenem antibiotics in the prior 90 days (aOR: 3.5; CI: 1.6-7.6), having ≥1 acute care hospital visit in the prior six months (aOR: 4.2; CI: 1.9-9.6), and receiving systemic fluconazole in the prior 90 days (aOR: 6.0; CI: 1.6-22.6). CONCLUSIONS: Targeted screening of patients in vSNFs with the above risk factors for C. auris can help identify colonized patients and facilitate implementation of infection control measures. Antimicrobial stewardship may be an important factor in the prevention of C. auris colonization. |
Notes from the field: large outbreak of botulism associated with a church potluck meal - Ohio, 2015
McCarty CL , Angelo K , Beer KD , Cibulskas-White K , Quinn K , Fijter S , Bokanyi R , Germain ES , Baransi K , Barlow K , Shafer G , Hanna L , Spindler K , Walz E , DiOrio M , Jackson BR , Luquez C , Mahon BE , Basler C , Curran K , Matanock A , Walsh K , Slifka KJ , Rao AK . MMWR Morb Mortal Wkly Rep 2015 64 (29) 802-803 On April 21, 2015, the Fairfield Medical Center (FMC) and Fairfield Department of Health contacted the Ohio Department of Health (ODH) about a patient suspected of having botulism in Fairfield County, Ohio. Botulism is a severe, potentially fatal neuroparalytic illness.* A single case is a public health emergency, because it can signal an outbreak. Within 2 hours of health department notification, four more patients with similar clinical features arrived at FMC's emergency department. Later that afternoon, one patient died of respiratory failure shortly after arriving at the emergency department. All affected persons had eaten at the same widely attended church potluck meal on April 19. CDC's Strategic National Stockpile sent 50 doses of botulinum antitoxin to Ohio. FMC, the Fairfield Department of Health, ODH, and CDC rapidly responded to confirm the diagnosis, identify and treat additional patients, and determine the source. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Nov 11, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure